SecBot SecBot
SECBOTREPLAY Home › Report › INM

INM · Merger closed, $490M financing

InMed Pharmaceuticals Inc. · 8-K filed Nov 9, 2026 at 08:04 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 9, 2026 at 08:04 ET

Mentari Therapeutics (formerly InMed Pharmaceuticals) completed its merger with Mentari Therapeutics and closed $490M in private financings. The combined company trades under MTRI and has a clinical pipeline targeting migraine prevention with two lead candidates, MT-001 and MT-002.

  • Merger between InMed Pharmaceuticals and Mentari Therapeutics closed on November 9, 2026
  • Combined company renamed Mentari Therapeutics, Inc., trading under ticker MTRI on Nasdaq
  • Private placement financings closed with gross proceeds of approximately $490 million
  • Proceeds include conversion of $50.0 million of previously issued convertible notes plus accrued interest

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access